A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Migraine in Children
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 12 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- H. Lundbeck A/S
- Last updated on ClinicalTrials.gov
- October 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- New England Institute for Clinical Research (NEICR) - Stamford · Stamford, CT
Florida · 3
- NW FL Clinical Research Group, LLC · Gulf Breeze, FL
- AGA Clinical Trials · Hialeah, FL
- University of South Florida (USF) - Tampa Campus · Tampa, FL
Kentucky · 1
- UK HealthCare-Kentucky Clinic · Lexington, KY
Ohio · 1
- Cincinnati Children's Hospital Medical Center-Burnet Campus · Cincinnati, OH
Texas · 1
- Road Runner Research (RRR) · San Antonio, TX
Virginia · 1
- Children's Specialty Group (CSG) · Norfolk, VA
West Virginia · 1
- Marshall Health-Marshall University Medical Center · Huntington, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.